Structure Therapeutics (GPCR) Change in Accured Expenses (2022 - 2026)

Structure Therapeutics' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$134000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 86.51% year-over-year to -$134000.0; the TTM figure through Mar 2026 stood at $22.4 million (up 129.28% YoY), while the FY2025 annual figure was $21.5 million, up 178.79% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$134000.0, down from $15.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $15.0 million in Q4 2025, with the low at -$3.0 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $2.5 million (2022), against an average of $2.5 million.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses jumped 5526.79% in 2023, then plunged 446.67% in 2024.
• Structure Therapeutics' Change in Accured Expenses stood at $56000.0 in 2022, then surged by 5526.79% to $3.2 million in 2023, then decreased by 4.03% to $3.0 million in 2024, then surged by 396.76% to $15.0 million in 2025, then tumbled by 100.89% to -$134000.0 in 2026.
• Business Quant data shows GPCR's Change in Accured Expenses at -$134000.0 in Q1 2026, $15.0 million in Q4 2025, and $3.9 million in Q3 2025.